Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Hepatitis 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrosis 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 27Cetuximab 17Radiotherapy 14Carboplatin 14pembrolizumab 11Paclitaxel 11Drug Therapy 8Radiotherapy, Intensity-Modulated 7Nivolumab 7Fluorouracil 7Erlotinib Hydrochloride 7Radiation 6Docetaxel 5130-nm albumin-bound paclitaxel 5Panitumumab 4Chemoradiotherapy 3Capecitabine 3Bevacizumab 3Albumin-Bound Paclitaxel 3Afatinib 3selinexor 2figitumumab 2Restraint, Physical 2Radiosurgery 2Methotrexate 2Lapatinib 2Everolimus 2Esophagectomy 2Cyclophosphamide 2zalutumumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Squamous Cell × bavituximab × Clear all
NCT04150900 2026-02-19

1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck

University of Maryland, Baltimore

Phase 2 Active not recruiting
7 enrolled 11 charts
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡